An interesting option is ibrutinib combined with anti-ROR1 monoclonal antibody in CLL, which is expected to have a great specificity for malignant B cells, and ROR1 levels are not reduced during ibrutinib therapy (187). Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.